|
Sign In to gain access to subscriptions and/or personal tools.
|
The serotonin syndrome and its treatment
P. K. Gillman
PO Box 8183, Mount Pleasant, Queensland 4740, Australia
Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no effective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT2 blockers cyproheptadine and chlorpromazine were identified and analysed. There is some evidence suggesting the efficacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT2receptors is 20–30 mg, which is higher than that used in the cases reported to date (4–16 mg).
Key Words: chlorpromazine • cyproheptadine • serotonin antagonists • serotonin syndrome • treatment
Journal of Psychopharmacology, Vol. 13, No. 1,
100-109 (1999)
DOI: 10.1177/026988119901300111
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S Lidder, H Ovaska, J R H Archer, S L Greene, A L Jones, P I Dargan, and D M Wood
Doctors' knowledge of the appropriate use and route of administration of antidotes in the management of recreational drug toxicity
Emerg. Med. J.,
December 1, 2008;
25(12):
820 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Shanmugam, B. Kent, T. Alsaiwadi, and R. Baskett
Serotonin syndrome following cardiac surgery
Interactive CardioVascular and Thoracic Surgery,
August 1, 2008;
7(4):
656 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Frank
Recognition and treatment of serotonin syndrome
Can Fam Physician,
July 1, 2008;
54(7):
988 - 992.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Koran M.D.
Obsessive-Compulsive Disorder: An Update for the Clinician
Focus,
January 1, 2007;
5(3):
299 - 313.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Easton and C. A. Marsden
Ecstasy: Are animal data consistent between species and can they translate to humans?
J Psychopharmacol,
March 1, 2006;
20(2):
194 - 210.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. L. Moses-Kolko, D. Bogen, J. Perel, A. Bregar, K. Uhl, B. Levin, and K. L. Wisner
Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
JAMA,
May 18, 2005;
293(19):
2372 - 2383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K Isbister and N. A Buckley
Clomipramine and neuroleptic malignant syndrome: Literature on adverse reactions to psychotropic drugs continues to confuse
BMJ,
April 2, 2005;
330(7494):
790 - 791.
[Full Text]
|
|
|
|
|
|
|
E. W. Boyer and M. Shannon
The Serotonin Syndrome
N. Engl. J. Med.,
March 17, 2005;
352(11):
1112 - 1120.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Precourt, M. Dunewicz, G. Gregoire, and D. R Williamson
Multiple Complications and Withdrawal Syndrome Associated with Quetiapine/Venlafaxine Intoxication
Ann. Pharmacother.,
January 1, 2005;
39(1):
153 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Elphick, W. Querbes, J. A. Jordan, G. V. Gee, S. Eash, K. Manley, A. Dugan, M. Stanifer, A. Bhatnagar, W. K. Kroeze, et al.
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Science,
November 19, 2004;
306(5700):
1380 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sato, Y. Okura, S. Minagawa, Y. Ohno, S. Fujita, D. Kondo, M. Hayashi, S. Komura, K. Kato, H. Hanawa, et al.
Life-Threatening Serotonin Syndrome in a Patient With Chronic Heart Failure and CYP2D6*1/*5
Mayo Clin. Proc.,
November 1, 2004;
79(11):
1444 - 1448.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. I Velez, G. Shepherd, B. A Roth, and F. L Benitez
Serotonin Syndrome with Elevated Paroxetine Concentrations
Ann. Pharmacother.,
February 1, 2004;
38(2):
269 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Locher, P. C. Ruben, J. Gut, and P. J. Rosenthal
5HT1A Serotonin Receptor Agonists Inhibit Plasmodium falciparum by Blocking a Membrane Channel
Antimicrob. Agents Chemother.,
December 1, 2003;
47(12):
3806 - 3809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.J.C. Dunkley, G.K. Isbister, D. Sibbritt, A.H. Dawson, and I.M. Whyte
The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity
QJM,
September 1, 2003;
96(9):
635 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mokhlesi, J. B. Leikin, P. Murray, and T. C. Corbridge
Adult Toxicology in Critical Care: Part II: Specific Poisonings
Chest,
March 1, 2003;
123(3):
897 - 922.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Blazer
Depression in Late Life: Review and Commentary
J Gerontol A Biol Sci Med Sci,
March 1, 2003;
58(3):
M249 - M265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J J Oliver, C Kelly, D Jarvie, S Denieul, and D N Bateman
Venlafaxine poisoning complicated by a late rise in creatine kinase: two case reports
Human and Experimental Toxicology,
August 1, 2002;
21(8):
463 - 466.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. Sorscher
Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist
J Psychopharmacol,
March 1, 2002;
16(2):
191 - 191.
[PDF]
|
|
|
|
|
|
|
F. Wappler, M. Fiege, and J. Schulte am Esch
Pathophysiological role of the serotonin system in malignant hyperthermia
Br. J. Anaesth.,
November 1, 2001;
87(5):
794 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Johkura, O. Hasegawa, and Y. Kuroiwa
Episodic encephalopathy with dilated pupils
Neurology,
April 24, 2001;
56(8):
1115 - 1116.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Stanford and S. C. Stanford
Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
J Psychopharmacol,
May 1, 1999;
13(3):
313 - 317.
[Abstract]
[PDF]
|
|
|
|
|
